Dr. Jan Bruder talks about his work at the Max Planck Institute for Molecular Biology in Münster Germany and his group’s use of automated high throughput drug screening program for ALS and Parkinson’s Disease.

Automated Stem Cell Based High Throughput Drug Screening for ALS and Parkinson’s

The Downstream Column (DsC) is an online publication targeting members of the biologics industry. Our intent is to provide a community to share expertise and best practices as well as discuss topics of interest. The Downstream Column covers areas important to the research, discovery, development, and manufacture of biologic therapeutics. Key industry coverage areas include: purification, formulation, fill/finish and QA/QC for cell and gene therapies, vaccines, biologics, and emerging therapeutic modalities.

Share Automated Stem Cell Based High Throughput Drug Screening for ALS and Parkinson’s

Sign up to save your podcasts

Automated Stem Cell Based High Throughput Drug Screening for ALS and Parkinson’s

Automated Stem Cell Based High Throughput Drug Screening for ALS and Parkinson’s